Annovis Alzheimer’s Program Sees Strong Phase 3 Progress
All 84 U.S. sites are active for Annovis Bio’s pivotal Phase 3 Alzheimer’s program, with the first participants reaching...
eClinical Tech News
Promising Barzolvolimab Data Shows Complete Urticaria Control
Celldex’s barzolvolimab delivered a mean UCT7 improvement of up to 8.6 points versus 2.5 for placebo at Week 12...
Avance Unveils Special CNS Center for Neuroscience Trials
Screen failure rates average 57% in CNS studies, compared with 36.3% across other therapeutic areas, and Avance Clinical points...
Hutchmed Completes Enrollment for Saffron Lung Cancer Trial
HUTCHMED and AstraZeneca completed randomization of 338 patients in SAFFRON, a global, open-label Phase III comparing all-oral savolitinib plus...
Spyre’s SPY003 Antibody Shows Positive Phase 1 Results
In a first-in-human Phase 1 study in healthy volunteers (n=59), Spyre Therapeutics’ extended half-life anti-IL-23 antibody SPY003 was well...
Lisata Touts Surprising Preclinical Certepetide ADC Data
Preclinical data presented at the World ADC San Diego meeting show that incorporating Lisata’s iRGD cyclic peptide, certepetide, as...
Hengrui/Kailera Phase 3 Obesity Trial Data Revealed in China
Hengrui’s once-weekly dual GLP-1/GIP agonist HRS9531 delivered 48-week mean weight loss of 11.2%, 17.4%, and 19.2% at 2 mg,...
Ascentage Pharma to Present Lisaftoclax Data at ASH 2025
In a registrational Phase II study of 72 evaluable patients with relapsed/refractory CLL/SLL after BTK inhibitor exposure, lisaftoclax monotherapy...
TransCon PTH: Latest 3-Year Renal Data for Adults Unveiled
Three-year follow-up from Ascendis Pharma’s PaTH Forward (Phase 2) and PaTHway (Phase 3) trials in adults with chronic hypoparathyroidism...
Biomea Doses First Patient in Phase I Study of Oral GLP-1
In preclinical studies, once-daily oral dosing of BMF-650 in obese cynomolgus monkeys produced dose-dependent reductions in food intake and...